Microdosing Ibogaine for Parkinson's: What One Case Study Found - Tobias Erny

Paul F. Austin and Tobias Erny explore low-dose ibogaine for Parkinson's disease: a published case report, GDNF, who responds, and drug safety. Find full show notes and links here: https://thethirdwave.co/podcast/episode-378/?ref=250 In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Tobias Erny, a Swiss iboga practitioner, researcher, and Co-Director of the Global Iboga Therapy Alliance. Tobias shares how ibogaine helped him end his own opiate addiction, and how that recovery grew into two decades of work with iboga, including a published case report on low-dose ibogaine for Parkinson's disease. Paul and Tobias explore why ibogaine may help some people living with Parkinson's, from GDNF, a growth factor that supports dopamine neurons, to its effects on mood and motivation. They also discuss how ibogaine differs from the whole iboga plant, why many patients don't respond, the medication interactions families should understand first, and why starting low and staying honest about uncertainty matters as research moves toward a clinical trial. Episode Links: Tobias Erny on LinkedIn Ibogaine and Parkinson's disease case report, Journal of Psychedelic Studies Talk with before and after video of a Parkinson's patient Episode Sponsors: The Microdosing Practitioner Certification at Psychedelic Coaching Institute. Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.